SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
CDKN2A/B deletions (19/19 patients with MLLT3 deletion), but was rarely observed with PTEN
deletion (1/11 patients with PTEN deletion). Patients with either CDKN2A/B deletions or PHF6
duplications frequently harbored NOTCH1 abnormalities: 24/36 patients (67%) and 15/26
patients (58%), respectively.
PDX primagrafts investigated engraftment latency and peripheral organ infiltration.
Primagrafts from patients harboring gene fusions typically engrafted at a slower rate (n=4, 70-
93 days) than primagrafts from patients harboring CDKN2A/B deletions (n=2, 32-53 days).
Conclusions
The majority of cases harbor rearrangements, structural variations and duplication/deletion
of genes associated with malignant transformation. We identified several co-occurring lesions
and mutually exclusive genomic abnormalities. Secondary PDX models investigating targeted
treatment strategies are ongoing.